Cetuximab-mediated NK:DC cross-talk expands T cells in cancer patients
Translational Relevance
The anti-epidermal growth factor receptor (EGFR) mAb cetuximab may act through blocking oncogenic signals and by inducing Fcγ receptor (FcγR) mediated antibody dependent cellular cytotoxicity (ADCC).
We show that polymorphism of FcγRIIIa (expressed by NK cells) does not correlate with clinical outcome of cetuximab-treated treated head and neck cancer (HNC) patients. Interestingly, however, cetuximab induces natural killer (NK) cell-dendritic cell (DC) cross-talk, which promotes DC maturation and CD8 + T cell priming, leading to tumor antigen spreading and Th1 cytokine release. The identification of EGFRspecific T cells in cetuximab treated HNC patients now permits a biomarker of response to be correlated with outcome in prospectively collected specimens. The implications of this finding include potential combinatorial vaccines with EGFR-specific mAbs, or in combination with immune checkpoint inhibitors to provide sustained CD8 + T activity after their induction by cetuximab-activated NK-DC priming.
Introduction
Tumor antigen (TA)-specific monoclonal antibodies (mAb) are clinically effective in a variety of malignancies. However, these results are only seen in a subset (~20%) of patients (1) . The large majority of treated patients, who are not likely to benefit from this therapy emphasizes the need to characterize the mechanisms underlying the activity of TA-specific mAb, and to optimize the selection of patients to be treated. In the present study we have utilized cetuximab, an epidermal growth factor receptor (EGFR)-specific, chimeric IgG1 isotype mAb that is FDA-approved for colorectal carcinoma (CRC) and head and neck carcinoma (HNC), as a model. Despite overexpression of EGFR in 80-90% of HNC, cetuximab is effective in only in 10-20% of patients (2, 3) .
A growing body of experimental and clinical evidence suggests that mAb-induced anti-tumor immunity underlie treated patients' clinical responses and may play a role in the differential clinical responses. Specifically, the statistically significant correlations of mAb-binding Fcγ receptor (FcγR) polymorphisms with clinical outcome in patients treated with rituximab (4, 5) trastuzumab (6, 7) , and cetuximab (8, 9) argue in favor of a role of immune cell activation in the clinical responses which have been described. Recently, trastuzumab emtansine (T-DM1) an Ab-drug conjugate showed significantly prolonged progression free and overall survival in breast cancer patients (10) and such a strategy may be enhanced by immune cell activation. However, the non absolute nature of the correlations in these malignancies (8, 9) , the strong influence of k-ras mutation (8) on clinical response to cetuximab in CRC and conflicting information about the beneficial effect of FcγRIIIa genotype in CRC patients (8, 9) , raise the possibility of additional immunological mechanisms in the clinical benefit from mAb-based immunotherapy. This possibility is supported by the growing evidence in animal model systems (11) and in clinical settings (12) that TA-specific mAb may elicit cellular immunity.
Therefore, in this study we have investigated whether the FcγRIIIa polymorphism on NK cells we and others have shown in in vitro experiments a significant correlation of FcγRIIIa polymorphism with the anti-tumor activity of cetuximab (13) . Furthermore, we have tested whether the interaction of cetuximab with FcγRIIIa on NK cells was required to trigger DC maturation and TA-specific cellular immune responses in HNC patients. We demonstrate for the first time that cetuximab-activated NK cells trigger cross-talk and maturation of DC in an FcγR and NK group 2, member D (NKG2D) dependent manner, and this results in TA-specific priming of CTL in cetuximab treated HNC patients. Lastly we have analyzed the mechanism (s) underlying the TA-specific immune response elicited by cetuximab and its potential clinical relevance.
Materials and Methods

Tumor cell lines
The HNC cell lines HLA-A2 -EGFR + PCI-15B, HLA-A2 -EGFR + and MAGE-3 + -JHU-029 (14) (15) (16) , the breast cancer cell line MCF-7 and the lymphoid T2 cell line were grown in IMDM (Sigma, St. Louis, MO) supplemented with 10% FBS (Cellgro, Manassas, VA), 2% L-glutamine and 1%
penicillin/streptomycin (Invitrogen, Carlsbad, CA) at 37 0 C in a 5% CO 2 , 95% humidity. Adherent tumor cells were detached by warm Trypsin-EDTA (0.25%) solution (Invitrogen, Carlsbad, CA).
Patients and demographics
The cohort of 107 cetuximab treated stage III/IV HNC patients described in Figure 1 combined 60 patients enrolled on two prospective, cetuximab containing clinical trial regimens, UPCI-05-003 and UPCI 05-005 and 47 additional patients treated with cetuximab off protocol, as described in performed on protocol patients who were receiving single agent cetuximab during the 6 month cetuximab maintenance phase of UPCI 05-003 (Table 1) , or other newly diagnosed HNC patients with stage III-IV disease while receiving cetuximab alone as primary treatment on a newly initiated, prospective phase II trial of single agent cetuximab (UPCI 08-013). The comparison (cetuximab-naïve) HNC cohorts were gender and age-matched, previously cetuximab untreated HNC patients. No patients were excluded as a result of prior treatments or performance status. Blood from cetuximab naïve HNC patients was drawn within the same period after completing therapy without cetuximab.
Antibodies and cytokines
The EGFR-specific chimeric IgG1 mAb cetuximab (Erbitux TM , BMS Imclone, Princeton, NJ) and the EGFR-specific human IgG2 mAb panitumumab (Vectibix, Amgen, Thousand Oaks, CA) were purchased from the University of Pittsburgh Hillman Cancer Center Pharmacy. The nonspecific control, human isotype IgG1 was purchased from Axxora LLC (San Diego, CA). FITC or PE-Cy7-anti-CD11c mAb (R & D systems), anti-CD80 mAb, anti-CD86 mAb, anti-CD83 mAb, anti-HLA-DR mAb, anti-CCR7 mAb (BD Biosciences Pharmingen) were purchased. Neutralizing anti-FcγRIIIa Ab, and PE-and FITCconjugated IgG isotypes for flow cytometry were purchased from BD Biosciences. FITC-goat-anti-human Fc specific IgG and FITC-goat anti-mouse IgG were purchased from Invitrogen. The antigen processing machinery (APM) components TAP-1-specific mAb NOB1 and TAP-2 specific mAb NOB2 were developed and characterized as described (19) . Anti-CXCL10 Ab, recombinant human GM-CSF, rec.
human IFN-α, rec. human IL-1β, rec. human IL-2, rec. human IL-4, rec. human IL-6, rec. human IL-7, PGE2, Poly I:C, and TNF-α were purchased from R&D Systems Inc (Minneapolis, MN). IFN-γ (Interferon-γ) was purchased from InterMune (Brisbane, CA).
Lymphocyte isolation from blood and PBMC
After approval by our Institutional Review Board (UPCI protocol 99-069), informed consent was obtained from each subject. Blood from healthy donors (Western PA blood bank) or HNC patients treated with cetuximab during or within one month of treatment. Lymphocytes were purified by Ficoll-Paque PLUS centrifugation (Amersham Biosciences, Uppsala, Sweden) and stored frozen. DC were generated as described previously (19) . NK cells and CD8 + T cells were purified using EasySep kits (Stem cell technologies, Vancouver, BC, Canada) and purity was >95% FcγRIIIa + , CD56 + , CD3 -(13).
PBMC were genotyped at FcγRIIIa (codon 158) using quantitative PCR (Applied Biosystems, Framingham, MA). Genomic DNA was extracted using the DNeasy Kit (Qiagen, Valencia, CA) following the manufacturer's protocol. Genomic DNA (5 to 50 ng) was added to a 25-μL reaction using 2X Taqman master mix (Applied Biosystems). Plates were analyzed using an ABI prism 7700 (13).
In vitro stimulation of EGFR-specific CD8 + T cells
Mature DC were incubated with autologous negatively isolated CD8 + T cells for 48 hr at 37 0 C with rhIL-2 (20 U/ml) and rhIL-7 (5ng/ml). On day 7 and weekly thereafter, lymphocytes were re-stimulated with autologous irradiated DC pulsed with peptide in culture medium supplemented with IL-2 (20 U/ml) and IL-7 (5 ng/ml). The stimulated CD8 + T cells were analyzed for TA specificity in IFN-γ ELISPOT at day 21 and then every 7 days thereafter. We have previously published a novel wild type EFGR 853-861 specific tetramer that recognizes EFGR 853-861 specific CTL and also shown that this specific tetramer recognizes EFGR 853-861 specific CTL clone that was generated by pulsing DC with EFGR 853-861 peptide in vitro (14) .
CTL lines and ELISPOT assay
IFN-γ ELISPOT assays were performed as described (14) . The MAGE-3 271-279 (FLWGPRALV) peptide and wild type EGFR 853-861 peptide (ITDFGLAKL) were produced by the peptide synthesis facility at the University of Pittsburgh, using F-moc technology (19, 20) . The HLA-A2-MAGE-3 271-279 tetramer was synthesized by the NIH Tetramer Facility (Emory University, Atlanta, GA). CTL lines were sorted using PE-labeled HLA-A2-EGFR 853-861 peptide loaded tetramers (14) and restimulated every 7-10 days. For ELISPOT assays, CD8 + T cells were seeded in triplicate (5x10 4 ) for bulk CD8 + T cells and 1x10 3 for CD8 + T cell clones) in multiscreen HTS plates. Synthetic peptides were then added to ELISPOT assays after APCs were seeded. After 18h, spots were enumerated using computer-assisted image analysis software.
Research. 
T cell chemotaxis assay
Cell migration assays was performed in 5.0μm pore-size 96 well polycarbonate filtration plate (Millipore). Briefly, the lower chambers were filled with cell-free culture supernatant collected from various experimental conditions. T cells (5x10 4 /100 μl of fresh media) were plated in the upper well.
Following a 4 hr incubation at 37 0 C, the upper wells containing filtration unit were gently removed and the cells in bottom chamber were counted by hemocytometer. After 4h incubation and counting, Cell numbers were plotted as the % migrated cells.
Statistical and patient follow up analysis
Disease specific survival of HNC patients was defined as the time elapsed from the first treatment with cetuximab until death from HNC. Patients were censored if they were alive at last follow-up or had died but were cancer-free at the time of death. FcγR genotype subclasses were tested for association with disease free survival with the log rank test. Other factors were tested for association with FcγR subclasses including cancer type (primary vs recurrent), disease site and whether the patient was treated on protocol.
These results were used to insure the conclusions regarding the influence of FcγR upon disease-specific mortality were not confounded by other potentially influential covariates. Two-tailed unpaired t-test was performed for statistical analysis to compare the significant difference between two groups and p < 0.05 was considered significant. T cell reactivity as measured by the ELISPOT assay was considered positive if the number of spots in test wells was significantly higher than that in background wells when using a onetailed permutation test for α ≤ 0.05.
Results
Survival of cetuximab treated HNC patients does not correlate with the FcγRIIIa polymorphism
We have previously demonstrated that NK cells expressing an FcγRIIIa V-encoding allele (at codon158) are more potent than NK cells expressing an FcγRIIIa F-encoding allele in ADCC against HNC cells in vitro (13). The clinical significance of our previously published in vitro data (13, 15) was then investigated in a cohort of 107 consecutive HNC patients treated with cetuximab at our institution and genotyped for polymorphic FcγRIIIa position 158 VV, VF or FF. Interestingly, FcγRIIIa genotype was not associated with disease specific survival (DSS) in this large cohort of cetuximab treated HNC patients ( Figure 1 and Table 1 ). The low frequency of the beneficial VV genotype (5%) (13), in light of the higher observed rate of clinical response (∼15-20%) (21) , raised the likelihood that an additional immune mechanism may play a role in the anti-tumor activity of cetuximab. Since cetuximab can activate NK cells (14), a significantly higher frequency of EGFR 853-861 -specific T cells was found in cetuximab-treated HNC patients than in cetuximab-naïve HNC patients ( Figure 
Enhancement by cetuximab of TA cross-presentation to cognate CTL in the presence of NK cells
Having observed a higher level of EGFR-specific T cells in cetuximab-treated HNC patients, we investigated in vitro whether cetuximab enhanced EGFR-specific T cell immunity and whether this effect was modulated by NK cells. We studied the effect of cetuximab with or without NK cells on DC crosspresentation using EGFR + , HLA-A2 -HNC cells to stimulate cognate CTL (19) . 
Enhancement by cetuximab-activated NK cells of non-EGFR (MAGE-3) cross-presentation to
MAGE-specific CTL
We selected another HNC cell line JHU-029, which expresses EGFR as well as MAGE-3 (14, 20) , 
Role of FcγRIIIa in the enhancement by cetuximab and NK cells of TAP-1 upregulation in DC
In the experiments described above ( Figure 2D ), we observed that DC cross-priming of EGFRspecific T cells was enhanced in the presence of cetuximab-activated NK cells. The latter cells had been previously shown to secrete high levels of Th1 cytokines and chemokines (13, 24) . Because these cytokines strongly upregulate the expression of certain APM components, such as TAP-1 and TAP-2, which are
Research. crucial for TA derived peptide presentation to cognate CTL (19), we investigated whether these APM components were upregulated in DC incubated with cetuximab-activated NK cells. Consistent with this notion, the enhanced level of TAP-1 was observed in DC that were co-cultured with cetuximab-activated NK cells, even if they were physically separated from the NK cells:PCI-15B cells co-culture (in the presence of cetuximab) through a transwell membrane ( Figure 4D ). The increase in TAP-1 expression in cetuximab-activated, NK cell treated DC was found after incubation with PCI-15B HNC cells (EGFR   high   ) but not with MCF-7 breast cancer cells. These results indicate that high EGFR expression on tumor cells is necessary for cetuximab-induced NK cell activation to induce DC maturation ( Figure 4E) . Also, the upregulation of TAP-1 in DC co-cultured with cetuximab-activated NK cells was abrogated by the blocking FcγRIIIa-specific mAb 3G8, but was not affected by a control isotype IgG1 ( Figure 4F ). Furthermore, incubation of NK cells with the EGFR-specific, IgG2 isotype mAb panitumumab which binds poorly to FcγRIIIa on NK cells (15, 23, 25) , failed to upregulate the expression of co-stimulatory molecules on DC, in accordance with the lack of effect on EGFR cross-priming (supplementary figure 1,2,3) . Thus, cetuximab-bound HNC cells activate NK cells through an FcγRIIIa-dependent mechanism, leading to APM component and costimulatory molecule upregulation in DC, manifested by their enhanced ability to mediate TA cross-presentation.
Enhancement by cetuximab of NK-DC cross-talk is NKG2D mediated
In light of the reciprocal activation of NK cells by DC ( Figure 4B ), we investigated the molecular mechanism underlying the interaction of cetuximab-activated NK cells cultured with mature DC.
Specifically blocking mAb for known modulators of NK-DC cross-talk were used to disrupt NK:DC interactions. Interestingly, only a blocking NKG2D-specific mAb abrogated the reciprocal activation of cetuximab-activated NK cells and DC, leading to significantly reduced IFN-γ secretion ( Figure 5A ). 
breast carcinoma bearing mice (7, 32) . Taken together, these results indicated that FcγRIIIa on NK cells could play a critical role in an immuno-naïve environment. However, this effect becomes less marked in 'immunocompetent' cancer patients, since we did not find a significant correlation between FcγRIIIa genotype and disease free survival in patients with HNC treated with cetuximab and radiotherapy and chemotherapy (Figure 1) , as seen in other cancer patients (26) (27) (28) (29) finding that an immunogenic EGFR-encoded CTL could be generated by pulsing DC with EGFR [853] [854] [855] [856] [857] [858] [859] [860] [861] peptide that could stimulate cognate CTL in vitro (14) . However, total recombinant EGFR protein was not used in this study as a source of TA since this would not mimic FcγRIIIa mediated effects and NK:DC cross talk that cetuximab stimulates.
Research. Although FcγRIIIa polymorphism dependent survival of cancer patients were reported in CRC cohorts (8, 9) , adaptive immune responses probably contribute in the cetuximab mediated immune responses, and may better predict clinical outcome of immunotherapy, because NK cells also provide helper function in shaping host adaptive immune responses. Moreover, the low frequency of VV patients often 'negatively' influences statistical analysis (26, 29) . These data clearly support the paradigm that anti-tumor mAb participate in the long term control of tumor in HNC patients, probably accounting for the clinical activity (30, 31, (33) (34) (35) .
To analyze the importance of FcγRIIIa, we used the two FDA-approved, EGFR-specific mAb cetuximab and panitumumab which bind the same epitope on EGFR (23, 25) , but differ in their isotype and FcγRIIIa affinity, to show that only cetuximab (IgG1) induced NK-DC crosstalk and DC cross-presentation ability, whereas panitumumab (IgG2) does not, despite their equal EGFR binding ( Figure 3B cellular immune response and to spread this priming to multiple TA, including private antigens. The effects observed can be blocked using a neutralizing IFN-γ mAb consistent with our previous findings regarding optimal APM upregulation in mature DC mediating cross-presentation (19) . However, the beginning of DC maturation is clearly dependent on secreted IFN-γ from ΝΚ cells whereas IL-12 might contribute for the cross-priming activities and reciprocal NK cell activation ( Figure 4B-C, 5 A-B) . We have also observed DC generated by 36h incubation with cytokines IL-1β, IL-6, PGE2 and TNF-α were used as a negative control in the assay. We previously showed that an immunogenic EGFR-encoded CTL could be generated by pulsing DC with EGFR 853-861 peptide that could stimulate cognate CTL in vitro (14) . Total recombinant EGFR protein was not used in this study as a source of TA since this would not mimic FcγRIIIa mediated effects and NK:DC cross talk that cetuximab stimulates. Data are representative of two independent, repeated experiments. A two-tailed unpaired t-test was performed for statistical analysis.
